Recombinant Human TGF-beta receptor type-2 (TGFBR2)

What is the molecular structure of TGFBR2 and how does it function in signal transduction?

TGFBR2 (transforming growth factor beta receptor type 2) is a transmembrane protein that spans the cell membrane with an extracellular domain that binds TGF-β ligands and an intracellular domain containing serine/threonine kinase activity. It serves as a critical component in the TGF-β signaling pathway, which regulates numerous cellular processes including proliferation, differentiation, motility, and apoptosis.

The signal transduction process begins when TGF-β binds to the extracellular domain of TGFBR2, activating it and allowing it to form a complex with TGFBR1 (ALK5) or alternatively with ALK1. This complex formation triggers intracellular signaling cascades through both SMAD-dependent and SMAD-independent pathways. The TGFBR2-mediated signaling can have varying effects depending on cellular context, functioning as a tumor suppressor in some settings by preventing uncontrolled cell growth .

What are the recommended methods for validating TGFBR2 knockdown in experimental systems?

Validating TGFBR2 knockdown requires a multi-level approach to ensure both reduction in expression and corresponding functional consequences. The following comprehensive validation strategy is recommended:

At the mRNA level:

• Semi-quantitative PCR or qPCR using specific TGFBR2 primers (e.g., forward 5′-TTA ACA GTG ATG TCA TGG CCA GCG-3′ and reverse 5′-AGA CTT CAT GCG GCT TCT CAC AGA-3′)

• Normalization with appropriate housekeeping genes (such as B2MG)

At the protein level:

• Western blotting using validated anti-TGFBR2 antibodies

• Flow cytometry to assess cell surface expression

For functional validation:

• TGF-β-induced SMAD2/3 phosphorylation assays

• Analysis of known TGF-β-responsive genes

• Phenotypic assays relevant to your research context

Essential controls should include non-targeting siRNA/shRNA, wild-type cells, and ideally rescue experiments with TGFBR2 re-expression to confirm specificity of observed effects .

What are the optimal reconstitution and storage conditions for recombinant TGFBR2 protein?

The proper handling of recombinant TGFBR2 protein is crucial for maintaining its functional integrity. Based on established protocols for similar recombinant proteins, the following guidelines are recommended:

For lyophilized protein:

• Store at -20°C to -80°C in a manual defrost freezer

• Avoid repeated freeze-thaw cycles

• Protect from light and moisture

Reconstitution protocols:

• For carrier-containing preparations: Reconstitute at approximately 20 μg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin

• For carrier-free preparations: Reconstitute at 5-100 μg/mL in sterile 4 mM HCl depending on the vial size

After reconstitution:

• Aliquot into single-use volumes to prevent multiple freeze-thaw cycles

• Store at -20°C to -80°C

• Use within 3-6 months of reconstitution

For working solutions:

• Prepare fresh dilutions in appropriate buffers immediately before use

• Include carrier proteins (e.g., 0.1% BSA) in working solutions to prevent non-specific binding to labware

How do TGFBR2 expression levels influence downstream signaling pathways and cellular responses?

TGFBR2 expression levels have a direct and nuanced impact on downstream signaling pathways and cellular responses. Research using regulatable TGFBR2 expression systems has demonstrated that:

SMAD pathway activation shows a direct correlation with TGFBR2 expression levels. As TGFBR2 expression increases, the phosphorylation of SMAD2/3 and subsequent nuclear translocation of SMAD complexes also increases proportionally.

MAPK-ERK signaling pathway activation is similarly dependent on TGFBR2 expression levels, with higher receptor expression leading to stronger pathway activation. This relationship appears to be particularly important for certain biological responses.

The induction of p21 expression and apoptosis requires relatively high TGFBR2 expression levels in some cell types. These responses appear to depend on the simultaneous activation of both SMAD and non-SMAD pathways, suggesting a threshold effect.

Experimental data indicates that differential expression of TGFBR2 serves as a mechanism for cells to selectively activate specific TGF-β-mediated responses. This allows for contextual specificity of TGF-β signaling, which may explain the diverse and sometimes contradictory effects of TGF-β in different cell types and disease states .

These findings demonstrate that precise control of TGFBR2 expression is a mechanism for determining the specificity of cellular responses to TGF-β stimulation.

What are the methodological approaches for developing a regulatable TGFBR2 expression system?

Developing a precisely controllable TGFBR2 expression system is valuable for studying receptor function and signaling dynamics. The following methodological approaches have proven effective:

Selection of inducible system:

• The RheoSwitch® inducible gene expression system has been successfully employed for TGFBR2 expression studies

• Alternative systems include Tet-On/Tet-Off or ecdysone-inducible systems

• Consider factors such as leakiness, induction ratio, and dose-response characteristics

Vector construction and delivery:

• Clone the TGFBR2 cDNA into the appropriate inducible expression vector

• Consider including epitope tags for detection if antibodies are limiting

• For viral delivery, utilize a 293T-based packaging cell line to produce viral particles containing the TGFBR2 transgene

Cell line generation and clonal selection:

• Infect target cells with viral supernatant (typically using 0.5 ml) in the presence of polybrene

• After 24 hours, remove viral supernatant and add selection antibiotics (e.g., Blasticidin at 6 μg/ml)

• Perform cloning by limiting dilution to isolate individual clones

• Screen clones for minimal baseline expression and robust induction of TGFBR2 after treatment with the inducer molecule

System validation:

• Confirm dose-dependent expression of TGFBR2 using Western blot or flow cytometry

• Validate functional coupling to downstream signaling by measuring SMAD phosphorylation

• Assess biological responses such as growth inhibition, apoptosis, or target gene expression

• Compare results to endogenous TGFBR2 expression in appropriate control cells

This approach allows detailed investigation of how different levels of TGFBR2 expression affect signal transduction and biological outcomes.

How can I analyze TGFBR2 genetic variants in disease association studies?

Analyzing TGFBR2 genetic variants in disease association studies requires a structured methodological approach:

Study design considerations:

• Implement multi-stage, case-control designs to validate initial findings

• Calculate appropriate sample sizes to ensure adequate statistical power

• Address population stratification through proper ethnic matching or statistical correction

• Collect comprehensive clinical and pathological information for phenotype correlation

Variant selection strategies:

• Focus on functional variants in coding regions, promoters, or splice sites

• Include previously reported disease-associated variants (e.g., TGFBR2 rs1078985 for breast cancer)

• Consider tagging SNPs to capture haplotype information efficiently

Statistical analysis approaches:

• Test multiple genetic models (additive, dominant, recessive)

• Calculate odds ratios with 95% confidence intervals

• Use appropriate statistical tests (χ² tests for genotype distributions)

• Apply multiple testing corrections (Bonferroni or FDR)

• Consider significance thresholds (e.g., P ≤ 0.05 for initial screening, more stringent thresholds for validation)

Bioinformatic analysis:

• Assess linkage disequilibrium patterns using tools like SNAP

• Predict functional consequences of variants using in silico prediction tools

• Analyze potential effects on protein structure, splicing, or expression

For example, in a study of breast cancer risk, TGFBR2 rs1078985 showed significant protective effects in both heterozygotes (OR: 0.84, 95%CI: 0.765–0.93) and homozygotes (OR: 0.73, 95%CI: 0.55–0.97) compared to major allele homozygotes. The association was consistently observed across study stages and remained significant after correction for multiple testing .

This methodological framework enables rigorous analysis of TGFBR2 genetic variants in relation to disease risk and progression.

What methodological approaches are recommended for studying TGFBR2-mediated apoptosis?

Studying TGFBR2-mediated apoptosis requires careful experimental design due to the context-dependent nature of TGF-β-induced cell death. The following methodological approaches are recommended:

Cell system selection:

• Choose cell types known to undergo TGF-β-induced apoptosis

• Consider using cell lines with regulatable TGFBR2 expression systems, as high TGFBR2 expression levels appear necessary for TGF-β-induced apoptosis in some systems

• Compare results across multiple cell types to establish generalizability

Apoptosis detection methods:

• Implement multiple complementary assays to ensure robust detection:

  • Annexin V/PI staining and flow cytometry for phosphatidylserine externalization

  • TUNEL assay for DNA fragmentation

  • Caspase activity assays (particularly caspase-3/7)

  • Mitochondrial membrane potential assessment

Signaling pathway analysis:

• Monitor both SMAD and non-SMAD pathway activation

• Use pathway-specific inhibitors to dissect the contribution of each pathway

• Assess p21 levels, which appear to be involved in TGF-β-induced apoptosis in certain cell types

• Evaluate expression of key apoptosis regulators (BCL-2 family proteins)

Temporal considerations:

• Include appropriate time points (apoptosis may require 24-72 hours after TGF-β stimulation)

• Perform time-course analysis of both signaling events and apoptotic markers

• Consider that early signaling events may be transient but crucial for later apoptotic responses

Data analysis should differentiate between apoptosis and other forms of cell death, and correlate the extent of apoptosis with the level of pathway activation to understand the relationship between TGFBR2 expression, signaling, and cell death.

How does TGFBR2 function in dental pulp cells and neurite outgrowth models?

TGFBR2 in dental pulp (DP) mesenchyme plays a specialized role in regulating differentiation and guiding neurite outgrowth during tooth mineralization and innervation. Methodological approaches for studying this function include:

Co-culture model development:

• Transwell inserts (e.g., Greiner Thincerts, 3 μm porosity) coated with 10 μg/ml laminin

• Seeding with approximately 50,000 cells/250 μl from appropriate sources

• For neuronal elements, Thy1-YFP transgenic mice provide fluorescently labeled neurons

• After 24 hours, apply mitotic inhibition using 1 mM uridine and 15 mM 5′-fluor-2′deoxyuridine to prevent mesenchymal cell overgrowth

• Maintain co-cultures for 4-5 days to allow neurite development

TGFBR2 manipulation:

• Implement Tgfbr2 knockdown using RNA interference techniques

• Validate knockdown efficiency using semi-qPCR with specific primers (forward 5′-TTA ACA GTG ATG TCA TGG CCA GCG-3′ and reverse 5′-AGA CTT CAT GCG GCT TCT CAC AGA-3′)

• Normalize expression data to appropriate housekeeping genes (e.g., B2MG)

Neurite outgrowth assessment:

• Quantitative analysis of neurite length, branching patterns, and directional growth

• Immunofluorescence for neuronal markers to differentiate neural structures

• Live imaging to track dynamic neurite behavior in real-time

This experimental approach allows for detailed investigation of how TGFBR2 in dental pulp cells influences neuronal development and provides insights into potential therapeutic applications for nerve regeneration and dental tissue engineering .

What are the experimental approaches for studying TGFBR2 mutations in cardiovascular disease models?

TGFBR2 mutations have been implicated in several cardiovascular disorders, particularly familial thoracic aortic aneurysm and dissection (TAAD) and Loeys-Dietz syndrome. The following experimental approaches are recommended for studying these conditions:

Model system selection:

• Cell-based models: Vascular smooth muscle cells, endothelial cells, and fibroblasts

• Tissue models: Aortic explants or engineered vascular tissues

• Animal models: Transgenic mice harboring TGFBR2 mutations that mimic human disease

• Patient-derived samples: Primary cells or induced pluripotent stem cells from affected individuals

Mutation introduction strategies:

• Site-directed mutagenesis to introduce specific disease-associated mutations (at least nine TGFBR2 gene mutations have been identified in familial TAAD)

• CRISPR/Cas9 gene editing to create isogenic cell lines differing only in the TGFBR2 mutation

• Conditional expression systems to study acute versus chronic effects

Vascular structure and function analysis:

• Histological assessment of vessel wall integrity and composition

• Biomechanical testing to evaluate tissue strength and elasticity

• In vivo imaging techniques (echocardiography, MRI) for aortic dimensions

• Vascular reactivity studies to assess functional alterations

Molecular signaling assessment:

• Analysis of both canonical (SMAD) and non-canonical TGF-β pathways

• Evaluation of extracellular matrix production and degradation

• Assessment of smooth muscle cell phenotype switching

• Comparison of signaling dynamics in mutant versus wild-type contexts

These approaches enable detailed characterization of how TGFBR2 mutations disturb signal transduction and lead to the specific aortic abnormalities associated with familial TAAD and related disorders .

What are common pitfalls in TGFBR2 research and how can they be addressed?

TGFBR2 research presents several technical challenges that can affect experimental outcomes. Here are common pitfalls and corresponding troubleshooting strategies:

Protein detection challenges:

• Pitfall: Low sensitivity in Western blot detection of TGFBR2

• Solution: Optimize antibody concentration and incubation conditions; consider using epitope-tagged TGFBR2 constructs; employ more sensitive detection methods; use larger amounts of starting material

Expression system issues:

• Pitfall: Leaky expression in inducible systems leading to baseline pathway activation

• Solution: Screen multiple clones for minimal baseline expression; optimize inducer concentration; consider alternative inducible systems with tighter regulation; include appropriate negative controls in all experiments

Signaling interference:

• Pitfall: Autocrine TGF-β production obscuring exogenous stimulation effects

• Solution: Use TGF-β neutralizing antibodies; culture cells in serum-free conditions before stimulation; include pathway inhibitor controls; carefully time and dose exogenous TGF-β administration

Functional assay variability:

• Pitfall: Inconsistent cellular responses to TGF-β stimulation

• Solution: Use freshly prepared, properly stored recombinant TGF-β; verify activity with functional assays; standardize cell density across experiments; control for passage number in cell lines

Knockdown/knockout efficiency:

• Pitfall: Incomplete TGFBR2 knockdown leading to residual signaling

• Solution: Test multiple siRNA/shRNA sequences; validate knockdown efficiency at both RNA and protein levels; consider CRISPR/Cas9 knockout for complete elimination; perform rescue experiments to confirm specificity

Addressing these common pitfalls will enhance the reliability and reproducibility of TGFBR2 research outcomes.

How can I optimize co-immunoprecipitation experiments for detecting TGFBR2 complexes?

Co-immunoprecipitation (co-IP) of TGFBR2 complexes presents unique challenges due to the transient nature of receptor interactions and membrane protein complexities. The following optimization strategies are recommended:

Sample preparation:

• Use chemical crosslinking (e.g., DSP or formaldehyde) to stabilize transient interactions

• Optimize cell lysis conditions using mild detergents (0.5-1% NP-40, CHAPS, or digitonin)

• Include protease and phosphatase inhibitors to preserve protein integrity

• Perform lysis and subsequent steps at 4°C to minimize complex dissociation

Antibody selection and validation:

• Test multiple antibodies targeting different epitopes of TGFBR2

• Validate antibody specificity using TGFBR2 knockout or knockdown controls

• Consider using epitope-tagged TGFBR2 constructs for enhanced detection

• Optimize antibody concentration and incubation time

Immunoprecipitation conditions:

• Pre-clear lysates to reduce non-specific binding

• Titrate antibody-to-lysate ratios to determine optimal conditions

• Include appropriate negative controls (isotype-matched IgG, untransfected cells)

• Consider using protein A/G magnetic beads for cleaner isolation

Detection strategies:

• Use highly sensitive detection methods for Western blotting

• Consider reciprocal co-IP (immunoprecipitate binding partner and detect TGFBR2)

• Validate interactions using complementary techniques (proximity ligation assay, FRET)

• For weak or transient interactions, consider mass spectrometry-based approaches

These optimizations will enhance the detection of physiologically relevant TGFBR2 complexes while minimizing artifacts and false positives.

What controls are essential when studying TGF-β-induced signaling through TGFBR2?

Robust experimental design for studying TGF-β-induced signaling through TGFBR2 requires comprehensive controls to ensure specificity, reproducibility, and physiological relevance:

Positive controls:

• Cell lines known to respond robustly to TGF-β stimulation

• Known TGF-β target genes (e.g., SMAD7, PAI-1) to confirm pathway activation

• Phospho-SMAD2/3 detection to verify canonical pathway activation

• Positive control stimuli for comparison (e.g., activin for SMAD2/3 activation)

Negative controls:

• TGFBR2 knockout or knockdown cells to demonstrate signaling specificity

• Heat-inactivated TGF-β to control for non-specific effects of the protein preparation

• Vehicle controls matched to the TGF-β formulation buffer

• Untreated cells to establish baseline signaling levels

Inhibitor controls:

• TGFBR1 kinase inhibitors (e.g., SB431542) to block downstream signaling

• TGF-β neutralizing antibodies to validate ligand specificity

• Pathway-specific inhibitors to dissect contribution of individual pathways

• Dose-response curves for all inhibitors to determine optimal concentrations

Time course controls:

• Multiple time points to capture both early and late signaling events

• Appropriate kinetic analysis to distinguish direct versus indirect effects

• Controls for protein and RNA turnover rates

• Synchronized cell populations to minimize cell cycle variability

Implementing these essential controls will enhance the rigor and reproducibility of TGFBR2 signaling studies and facilitate meaningful interpretation of experimental results.

Recombinant Human TGFBR2 protein specifications

The proper handling and reconstitution of recombinant TGFBR2 protein is essential for maintaining its functional integrity in research applications .

TGFBR2 expression impact on signaling pathways and cellular responses

Research using regulatable TGFBR2 expression systems has demonstrated that both SMAD signaling and MAPK-ERK signaling activation levels correlate directly with TGFBR2 expression levels. Furthermore, p21 induction and TGF-β-induced apoptosis appear to depend on relatively high TGFBR2 expression and on the simultaneous activation of both signaling pathways .